



LISDEXAMFETAMINE DIMESYLATE



Rubió 55
years

We are pharmacypathfinders

**Long-acting psychostimulant prodrug for the treatment
of Attention Deficit Hyperactivity Disorder (ADHD)**



General Information

Name: Lisdexafetamine Rubió
API: Lisdexafetamine dimesylate
Main Presentations: 20/30/40/50/60/70 mg of 30 capsules

Indications

Lisdexafetamine Rubió is a treatment for Attention Deficit Hyperactivity Disorder (ADHD). It is used:

- In children, young people and adults who have previously taken a methylphenidate treatment that inadequately treated their ADHD.
- Lisdexafetamine Rubió is not used as a treatment for ADHD in children under 6 years of age because it is not known if it is safe or of benefit in such young people.

Characteristics

Lisdexafetamine Rubió contains the active substance lisdexafetamine dimesylate which helps with the brain activity. It helps improve the attention, helps to concentrate and makes the patient less impulsive.

Lisdexafetamine Rubió is a long acting medicine which works gradually over a 13 hour time period.

Lisdexafetamine Rubió improves the activity of certain parts of the brain which are under-active. The medicine can help improve attention, concentration and reduce impulsive behaviour^{1,2,3}

Registration and Marketing Authorization

- CTD dossier will be available with Bioequivalence (BE) with Elvanse®/ Vyvanse® in Q1 2026.
- Registration in new countries as Generic of Elvanse®, preferable as First Generic.

Deal Design

- We are looking for Distributors and/or Licensing Partners having a relevant sales structure in CNS to do a proper promotion of the products or with a long sales expertise in the Generic Business to market it as a generic of Elvanse®.
- Deal design consisting of a Supply & Distribution and/or Licensing Agreement to market the Finished Product manufactured by Laboratorios Rubió, S.A.
- We are searching for the best Partners to develop trustful, fruitful and long term business partnerships.

Founded

1968

Location

Castellbisbal, Barcelona, Spain

Main Focus

CNS, Nephrology/Urology, Cardiovascular, Gastroenterology, Rheumatology/Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubió

For 55 years Laboratorios Rubió, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Laboratorios Rubió's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnership Strategy

Laboratorios Rubió has established a strong network of partnerships through in and out activities and commercial distribution agreements. Laboratorios Rubió has been in the export business since 1982 and has alliances in over 60 countries. Laboratorios Rubió is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubió, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
Fax: +34 937 721 602
www.laboratoriosrubio.com

Contact:

export@labrubio.com

REFERENCES: 1. Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, et al. A post hoc comparison of the effects of lisdexafetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents. *CNS Drugs* 2013; 27: 743-751. 2. Coghill DR, Joseph A, Sikirica V, Kosinski M, Bliss C, Huss M. Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHD. *J Atten Disord*. 2017 Aug 24;23(13):1578-1591. 3. Coghill, D.R., Werner-Kiechle, T., Farahbakhshian, S. et al. Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses. *Eur Child Adolesc Psychiatry* 30, 809-821 (2021).